{"id":"W2768980003","doi":"10.1016/s1470-2045(17)30717-9","title":"Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":589,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Alberta; BC Cancer Agency","funders":"National Institute for Health and Care Research; Puma Biotechnology","keywords":"Medicine; Neratinib; Trastuzumab; Internal medicine; Breast cancer; Oncology; Clinical endpoint; Placebo; Regimen; Metastatic breast cancer; Adverse effect; Cancer; Clinical trial; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003656813,0.002207806,0.005050621,0.0004660369,0.0004583111,0.00159487,0.00126331,0.002285412,0.00514436],"category_scores_gemma":[0.003024952,0.0006953563,0.004394197,0.0005563044,0.001497472,0.002510563,0.0005829897,0.004596834,0.001039049],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009729541,"about_ca_system_score_gemma":0.0008754494,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009790853,"about_ca_topic_score_gemma":0.002201162,"domain_scores_codex":[0.9986429,0.0007343357,0.00008698038,0.0002296667,0.00008360564,0.0002225157],"domain_scores_gemma":[0.9985062,0.0004913181,0.0003563138,0.0001733728,0.00009142102,0.000381346],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9888529,0.001132547,0.0003108578,0.0005127686,0.001520717,0.00002923269,0.00003136859,0.0003042626,0.0007890726,0.00007557468,0.0004000105,0.006040598],"study_design_scores_gemma":[0.9722939,0.02425778,0.001388479,0.00004123815,0.0009188283,0.00003709464,0.00002508245,0.0002843897,0.0001883302,0.0001750962,0.0003718367,0.00001803378],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9762468,0.01515486,0.001290504,0.00104998,0.001055766,0.001706925,0.00142889,0.0001924126,0.001873843],"genre_scores_gemma":[0.9867225,0.004634472,0.001119351,0.00106643,0.0004391076,0.001397973,0.001436515,0.00004223547,0.003141293],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00514436,"threshold_uncertainty_score":0.01933932,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09916280515671266,"score_gpt":0.4624950642930083,"score_spread":0.3633322591362956,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}